• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Eydisbio Inc.

Monday, June 03, 2024
CP
Orphan and Rare Disease
EydisBio is an emerging pharmaceutical company located in Durham, NC. EydisBio is focused on developing small molecule inhibitors towards difficult to treat diseases. Our primary program has focused on developing selective TAK1 inhibitors for the treatment of autoimmune diseases such as systemic sclerosis and rheumatoid arthritis. Our team of experienced drug developers help guide our program and have demonstrated great success in being the first group to selectively target TAK1 therapeutically in pre-clinical models. Our pioneering studies have shown the therapeutic potential of TAK1 in pre-clinical models and our immediate goal is to advance a lead candidate towards first in human studies.
Eydisbio Inc.
Company Website: http://www.eydisbio.com
Lead Product in Development: TAK1 inhibitor for autoimmune disease
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City

Durham

Company HQ State

North Carolina

Company HQ Country

United States

CEO/Top Company Official

Timothy Haystead PhD

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS